A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2017
At a glance
- Drugs MP 0274 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Molecular Partners AG
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2016 According to Molecular Partners AG media release, first regulatory submission for phase 1 with MP0274 for the treatment of HER2-positive solid tumor has been planned for 1Q 2017.
- 02 May 2016 New trial record